Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington, N. George Mikhaeel, Lale Kostakoğlu, et al.
Journal of Clinical Oncology (2014) Vol. 32, Iss. 27, pp. 3048-3058
Open Access | Times Cited: 1474

Showing 26-50 of 1474 citing articles:

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
Sally F. Barrington, Regine Kluge
European Journal of Nuclear Medicine and Molecular Imaging (2017) Vol. 44, Iss. S1, pp. 97-110
Open Access | Times Cited: 241
Positron Emission Tomography–Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial
Ulrich Dührsen, Stefan Müller, Bernd Hertenstein, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 20, pp. 2024-2034
Closed Access | Times Cited: 208
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
Sattva S. Neelapu, Michael Dickinson, Javier Muñoz, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 735-742
Open Access | Times Cited: 196
Revised International Pediatric Non-Hodgkin Lymphoma Staging System
Angelo Rosolen, Sherrie L. Perkins, CR Pinkerton, et al.
Journal of Clinical Oncology (2015) Vol. 33, Iss. 18, pp. 2112-2118
Open Access | Times Cited: 193
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
Olivier Casasnovas, Réda Bouabdallah, Pauline Brice, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 2, pp. 202-215
Open Access | Times Cited: 185
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
David M. Kurtz, Mohammad Shahrokh Esfahani, Florian Scherer, et al.
Cell (2019) Vol. 178, Iss. 3, pp. 699-713.e19
Open Access | Times Cited: 178
Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma
Anne‐Ségolène Cottereau, Hélène Lanic, Sylvain Mareschal, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 15, pp. 3801-3809
Open Access | Times Cited: 171
PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study
Sally F. Barrington, Amy A. Kirkwood, Antonella Franceschetto, et al.
Blood (2016) Vol. 127, Iss. 12, pp. 1531-1538
Open Access | Times Cited: 170
Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
Anne‐Ségolène Cottereau, Annibale Versari, Annika Loft, et al.
Blood (2018) Vol. 131, Iss. 13, pp. 1456-1463
Open Access | Times Cited: 162
High total metabolic tumor volume at baseline predicts survival independent of response to therapy
Laëtitia Vercellino, Anne‐Ségolène Cottereau, Olivier Casasnovas, et al.
Blood (2020) Vol. 135, Iss. 16, pp. 1396-1405
Open Access | Times Cited: 148
A review of prognostic and predictive biomarkers in breast cancer
Elaheh Tarighati, Hadi Keivan, Hojjat Mahani
Clinical and Experimental Medicine (2022)
Closed Access | Times Cited: 127
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Elise A. Olsen, Sean Whittaker, Rein Willemze, et al.
Blood (2021) Vol. 140, Iss. 5, pp. 419-437
Open Access | Times Cited: 112
Role of Artificial Intelligence in Radiogenomics for Cancers in the Era of Precision Medicine
Sanjay Saxena, Biswajit Jena, Neha Gupta, et al.
Cancers (2022) Vol. 14, Iss. 12, pp. 2860-2860
Open Access | Times Cited: 86
A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
Michael Dickinson, Pere Barba, Ulrich Jäger, et al.
Cancer Discovery (2023) Vol. 13, Iss. 9, pp. 1982-1997
Open Access | Times Cited: 70
Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)
Julia Chisholm, Henry Mandeville, Madeleine Adams, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 998-998
Open Access | Times Cited: 17
B-cell non-Hodgkin lymphomas
Elisabeth Silkenstedt, Gilles Salles, Elı́as Campo, et al.
The Lancet (2024) Vol. 403, Iss. 10438, pp. 1791-1807
Closed Access | Times Cited: 17
Imaging for Staging and Response Assessment in Lymphoma
Sarah A. Johnson, Anita Kumar, Matthew J. Matasar, et al.
Radiology (2015) Vol. 276, Iss. 2, pp. 323-338
Closed Access | Times Cited: 173
Non-Hodgkin Lymphoma: Diagnosis and Treatment
Stephen M. Ansell
Mayo Clinic Proceedings (2015) Vol. 90, Iss. 8, pp. 1152-1163
Open Access | Times Cited: 169
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies
Judith Trotman, Stefano Luminari, Sami Boussetta, et al.
The Lancet Haematology (2014) Vol. 1, Iss. 1, pp. e17-e27
Closed Access | Times Cited: 159
Guidelines for the management of diffuse large B‐cell lymphoma
Sridhar Chaganti, Tim Illidge, Sally F. Barrington, et al.
British Journal of Haematology (2016) Vol. 174, Iss. 1, pp. 43-56
Open Access | Times Cited: 158
Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study
Pam K. Mangat, Susan Halabi, Suanna S. Bruinooge, et al.
JCO Precision Oncology (2018), Iss. 2, pp. 1-14
Open Access | Times Cited: 157
Primary mediastinal large B-cell lymphoma
Maurizio Martelli, Andrés J.M. Ferreri, Alice Di Rocco, et al.
Critical Reviews in Oncology/Hematology (2017) Vol. 113, pp. 318-327
Open Access | Times Cited: 151
How I treat posttransplant lymphoproliferative disorders
Daan Dierickx, Thomas Tousseyn, Olivier Gheysens
Blood (2015) Vol. 126, Iss. 20, pp. 2274-2283
Open Access | Times Cited: 148
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, et al.
Journal of the National Comprehensive Cancer Network (2017) Vol. 15, Iss. 5, pp. 608-638
Open Access | Times Cited: 139
Staging and response assessment in lymphomas: the new Lugano classification.
Bruce D. Cheson
PubMed (2015) Vol. 4, Iss. 1, pp. 5-5
Closed Access | Times Cited: 137

Scroll to top